

FILE 'HOME' ENTERED AT 11:46:07 ON 03 JUL 2002

=> index medicine bioscience pharmacology meetings business polymers chemistry
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, ...' ENTERED AT 11:47:08 ON 03 JUL 2002

106 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s exendin

37	FILE ADISALERTS
6	FILE ADISINSIGHT
2	FILE ADISNEWS
246	FILE BIOSIS
50	FILE BIOTECHNO
23	FILE CANCERLIT
186	FILE CAPLUS
95	FILE DDFU
1575	FILE DGENE
20	FILE DRUGNL
101	FILE DRUGU
5	FILE EMBAL
136	FILE EMBASE
110	FILE ESBIOBASE
10	FILE IFIPAT
2	FILE IPA
6	FILE JICST-EPLUS
24	FILE LIFESCI
144	FILE MEDLINE
2	FILE NAPRALERT
76	FILE NLDB
69	FILE PASCAL
33	FILE PHIN
217	FILE SCISEARCH
57	FILE TOXCENTER
29	FILE USPATFULL
1	FILE USPAT2
7	FILE AGRICOLA
3	FILE BIOBUSINESS
14	FILE BIOCOPMERCCE
2	FILE BIOTECHABS
2	FILE BIOTECHDS
13	FILE CABAB
28	FILE CIN
5	FILE CONFSCI

46 FILES SEARCHED...

6	FILE DRUGUPDATES
7	FILE FEDRIP
3	FILE FROSTI
5	FILE GENBANK
3	FILE PHAR
155	FILE PROMT
31	FILE WPIDS
31	FILE WPINDEX
1	FILE BABS
32	FILE CBNB
116	FILE INVESTTEXT

80 FILES SEARCHED...
8 FILE IMSPROFILES
0* FILE TULSA2
105 FILES SEARCHED...

47 FILES HAVE ONE OR MORE ANSWERS, 106 FILES SEARCHED IN STNINDEX

L1 QUE EXENDIN

=> file hits
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE ENTRY	TOTAL SESSION
8.48	8.90

FILE 'DGENE' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 11:56:37 ON 03 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PROMT' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:56:37 ON 03 JUL 2002

FILE 'EMBASE' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'INVESTTEXT' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'ESBIOBASE' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DRUGU' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'NLDB' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'PASCAL' ENTERED AT 11:56:37 ON 03 JUL 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 ACS

FILE 'BIOTECHNO' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PHIN' ENTERED AT 11:56:37 ON 03 JUL 2002

• COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'CBNB' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'WPIDS' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'USPATFULL' ENTERED AT 11:56:37 ON 03 JUL 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CIN' ENTERED AT 11:56:37 ON 03 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'LIFESCI' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CANCERLIT' ENTERED AT 11:56:37 ON 03 JUL 2002

FILE 'DRUGNL' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'BIOCOMMERCE' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'CABA' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'IFIPAT' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPROFILES' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 IMSWORLD Publications Ltd.

FILE 'AGRICOLA' ENTERED AT 11:56:37 ON 03 JUL 2002

FILE 'FEDRIP' ENTERED AT 11:56:37 ON 03 JUL 2002

FILE 'ADISINSIGHT' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'JICST-EPLUS' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'DRUGUPDATES' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'CONFSCI' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'GENBANK' ENTERED AT 11:56:37 ON 03 JUL 2002

FILE 'BIOBUSINESS' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'FROSTI' ENTERED AT 11:56:37 ON 03 JUL 2002

COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'PHAR' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'ADISNEWS' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'IPA' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'NAPRALERT' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'USPAT2' ENTERED AT 11:56:37 ON 03 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BABS' ENTERED AT 11:56:37 ON 03 JUL 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

=> set plurals on perm
SET COMMAND COMPLETED

=> s 11 and erythema
L2 213 FILE DGENE
L3 0 FILE BIOSIS
L4 0 FILE SCISEARCH
L5 1 FILE CAPLUS
L6 0 FILE PROMT
L7 0 FILE MEDLINE
L8 0 FILE EMBASE
L9 0 FILE INVESTTEXT
L10 0 FILE ESBIOBASE
L11 0 FILE DRUGU
L12 0 FILE NLDB
L13 0 FILE PASCAL
L14 0 FILE TOXCENTER
L15 0 FILE BIOTECHNO
L16 0 FILE ADISALERTS
L17 0 FILE PHIN
L18 0 FILE CBNB
L19 1 FILE WPIDS
L20 1 FILE USPATFULL
L21 0 FILE CIN
L22 0 FILE LIFESCI
L23 0 FILE CANCERLIT
L24 0 FILE DRUGNL
L25 0 FILE BIOCOMMERCE

COMMAND INTERRUPTED

L26 0 FILE IFIPAT
L27 0 FILE IMSPROFILES
L28 0 FILE AGRICOLA
L29 0 FILE FEDRIP
L30 0 FILE ADISINSIGHT
L31 0 FILE JICST-EPLUS
L32 0 FILE DRUGUPDATES
L33 0 FILE EMBAL
L34 0 FILE CONFSCI
L35 0 FILE GENBANK
L36 0 FILE BIOBUSINESS

```
L37      0 FILE FROSTI
L38      0 FILE PHAR
L39      0 FILE ADISNEWS
L40      0 FILE IPA
L41      0 FILE NAPRALERT
L42      0 FILE BIOTECHDS
L43      0 FILE USPAT2
L44      0 FILE BABS
```

TOTAL FOR ALL FILES

L45 216 L1 AND ERYTHEMA

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> dup rem 145

DUPLICATE IS NOT AVAILABLE IN 'DGENE, INVESTTEXT, BIOCOMMERCE, IMSPROFILES,
FEDRIP, ADISINSIGHT, DRUGUPDATES, GENBANK, PHAR, ADISNEWS'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L45

L46 215 DUP REM L45 (1 DUPLICATE REMOVED)

=> s 11 and glucagonoma

```
L47      213 FILE DGENE
L48      0 FILE BIOSIS
L49      0 FILE SCISEARCH
L50      1 FILE CAPLUS
L51      0 FILE PROMT
L52      0 FILE MEDLINE
L53      0 FILE EMBASE
L54      0 FILE INVESTTEXT
L55      0 FILE ESBIOBASE
L56      0 FILE DRUGU
L57      0 FILE NLDB
L58      0 FILE PASCAL
L59      0 FILE TOXCENTER
L60      0 FILE BIOTECHNO
L61      0 FILE ADISALERTS
L62      0 FILE PHIN
L63      0 FILE CBNB
L64      2 FILE WPIIDS
L65      0 FILE USPATFULL
L66      0 FILE CIN
L67      0 FILE LIFESCI
L68      0 FILE CANCERLIT
L69      0 FILE DRUGNL
L70      0 FILE BIOCOMMERCE
```

COMMAND INTERRUPTED

```
L71      0 FILE IFIPAT
L72      0 FILE IMSPROFILES
L73      0 FILE AGRICOLA
L74      0 FILE FEDRIP
L75      0 FILE ADISINSIGHT
L76      0 FILE JICST-EPLUS
L77      0 FILE DRUGUPDATES
L78      0 FILE EMBAL
L79      0 FILE CONFSCI
L80      0 FILE GENBANK
L81      0 FILE BIOBUSINESS
L82      0 FILE FROSTI
L83      0 FILE PHAR
L84      0 FILE ADISNEWS
L85      0 FILE IPA
L86      0 FILE NAPRALERT
L87      0 FILE BIOTECHDS
L88      0 FILE USPAT2
```

TOTAL FOR ALL FILES

L90 216 L1 AND GLUCAGONOMA

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> d 190 1-216 ibib abs

L90 ANSWER 1 OF 216 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94200 peptide DGENE

TITLE: Lowering plasma glucagon using **exendin**, an
exendin agonist, a modified **exendin** or a
modified **exendin** agonist, useful for treating
hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94200 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L90 ANSWER 2 OF 216 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94199 peptide DGENE

TITLE: Lowering plasma glucagon using **exendin**, an
exendin agonist, a modified **exendin** or a
modified **exendin** agonist, useful for treating
hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94199 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma

glucagon in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L90 ANSWER 3 OF 216 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94198 peptide DGENE

TITLE: Lowering plasma glucagon using **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94198 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L90 ANSWER 213 OF 216 DGENE (C) 2002 THOMSON DERWENT
 ACCESSION NUMBER: AAB07401 Protein DGENE
 TITLE: Lowering plasma glucagon using **exendin**, an
exendin agonist, a modified **exendin** or a
 modified **exendin** agonist, useful for treating
 hyperglucagonemia and diabetes -
 INVENTOR: Young A; Gedulin B
 PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
 PATENT INFO: WO 2000041548 A2 20000720 96p
 APPLICATION INFO: WO 2000-US942 20000114
 PRIORITY INFO: US 1999-116380 19990114
 US 1999-132017 19990430
 US 2000-175365 20000110
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-490999 [43]
 AN AAB07401 Protein DGENE
 AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L90 ANSWER 214 OF 216 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:493318 CAPLUS
 DOCUMENT NUMBER: 133:129880
 TITLE: Methods using an **exendin** or related substance for glucagon suppression
 INVENTOR (S): Young, Andrew; Gedulin, Bronislava
 PATENT ASSIGNEE (S): Amylin Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041548	A2	20000720	WO 2000-US942	20000114
WO 2000041548	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143989	A2	20011017	EP 2000-902415	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007823	A	20011120	BR 2000-7823	20000114
NO 2001003469	A	20010914	NO 2001-3469	20010712
PRIORITY APPLN. INFO.:			US 1999-116380P	P 19990114
			US 1999-132017P	P 19990430
			US 2000-175365P	P 20000110

AB Methods are provided for use of an **exendin**, an **exendin** agonist, or a modified **exendin** or **exendin** agonist having an **exendin** or **exendin** agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.

L90 ANSWER 215 OF 216 WPIDS (C) 2002 THOMSON DERWENT
 ACCESSION NUMBER: 2002-012518 [02] WPIDS
 CROSS REFERENCE: 2000-595483 [50]; 2000-680964 [50]
 DOC. NO. CPI: C2002-003289
 TITLE: Use of glycogen phosphorylase inhibitor in prophylactic treatment of Type II diabetes.
 DERWENT CLASS: B02
 INVENTOR(S): TREADWAY, J L
 PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
 COUNTRY COUNT: 31
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1136071	A2	20010926 (200202)*	EN	78	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2001028130	A	20010927 (200202)			
CA 2341344	A1	20010922 (200203)	EN		
JP 2001302546	A	20011031 (200204)		70	
HU 2001001158	A2	20020228 (200223)			
KR 2001092696	A	20011026 (200223)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1136071	A2	EP 2001-301979	20010305
AU 2001028130	A	AU 2001-28130	20010320
CA 2341344	A1	CA 2001-2341344	20010320
JP 2001302546	A	JP 2001-78839	20010319
HU 2001001158	A2	HU 2001-1158	20010321
KR 2001092696	A	KR 2001-14306	20010320

PRIORITY APPLN. INFO: US 2000-191381P 20000322

AN 2002-012518 [02] WPIDS
 CR 2000-595483 [50]; 2000-680964 [50]
 AB EP 1136071 A UPAB: 20020114

NOVELTY - A glycogen phosphorylase inhibitor (G1) is used in the manufacture of a medicament for prophylactically treating an individual with increased risk of developing Type II diabetes mellitus

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a pharmaceutical composition comprising (G1) and a non-glycogen phosphorylase inhibiting anti-diabetic agent (NG1); and
- (2) a pharmaceutical composition comprising (G1) and an anti-obesity agent.

ACTIVITY - Antidiabetic.

MECHANISM OF ACTION - Glycogen phosphorylase inhibitor.

No biological data is given.

USE - For prophylactically treating a person having risk associated with Type 2 diabetes (particularly risk associated with insulin resistance and/or hyperinsulinemia; environmental or genetic Type 2 diabetes predisposing disease states or conditions (e.g. person with a family history of diabetes); race and/or ethnicity (e.g. individuals from

African-American, Hispanic, Native American, Asian, or Pacific Islander population); genetic mutations affecting beta -cell function (e.g. defect on chromosome 12, gene HNF-1 alpha (MODY3), chromosome 7, gene glucokinase (MODY2), chromosome 20, gene HNF-4a (MODY1), or mitochondrial DNA); genetic defects in insulin action (e.g. genetic mutation leading to Type A insulin resistance, acanthosis nigricans, leprechaunism, Rabson-Mendenhall syndrome, lipoatrophic diabetes, or a genetic mutation or mutations in the insulin receptor, IRS proteins, glucose transporters, PC-1, glucokinase, UCP-1, beta 3 adrenergic receptor gene); presence of excess adipose tissue or clinically diagnosed obesity (e.g. central obesity); clinical chemistry or diagnostic testing signifying a pre-diabetic state (e.g. impaired glucose tolerance, impaired fasting glucose, or hyperglycemia relative to normoglycemia); physiologic and endocrine changes associated with growth, development, or aging (e.g. menopausal, pubescent, or aged individuals); diet or eating behaviors (e.g. consumption of high fat or high carbohydrate diets, experiencing prolonged fasting or starvation, having anorexia nervosa and bulimia); abnormal cardiovascular or blood lipid parameters (e.g. hypertension, HDL cholesterol level up to 35 mg/dl and/or TG levels of at least 250 mg/dl and metabolic syndrome); reproductive status (e.g. pregnancy, a history of gestational diabetes and macrosomia); muscle wasting (e.g. aging, starvation, exposure to anti-gravity environments and paralysis resulting from spinal cord injury); polycystic ovary syndrome; organ disease or dysfunction (e.g. liver cirrhosis and renal disease); metabolic disturbances; endocrine disorders or endocrinopathies (e.g. hyperandrogenism, thyrotoxicosis, hyperthyroidism, insulinoma, glucagonoma, somatostatinoma, aldosteroma, Cushing's Syndrome, pheochromocytoma, acromegaly and hypercortisolemia); pathophysiologic states (e.g. infection, congenital rubella, cytomegalovirus, toxemia, uremia, sepsis and trauma); immune-mediated disease (e.g. stiff man syndrome or the production of anti-insulin receptor antibodies); drug or chemical exposure (e.g. glucocorticoids, cytokines, alpha -interferon, thyroid hormone, TNF alpha, thiazides, estrogen-containing products, beta-blockers, nicotinic acid, serotonin receptor-targeted antipsychotics or antidepressants, vacor, diazoxide, dilantin, and HIV protease inhibitors); genetic syndrome associated with diabetes (e.g. Down's Syndrome, Klinefelter's Syndrome, Wolfram's Syndrome, Friedreich's Syndrome, Huntington's chorea, Laurence-Moon-Biedl Syndrome, myotonic dystrophy, porphyria, Prader-Willi Syndrome and Alzheimer's Disease); and detrimental effects caused by the administration of prolonged, elevated doses of insulin and/or the presence of ketoacidosis) (all claimed).

Dwg.0/0

L90 ANSWER 216 OF 216 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2000-490999 [43] WPIDS

CROSS REFERENCE: 2000-514584 [46]; 2001-514422 [47]

DOC. NO. CPI: C2000-147547

TITLE: Lowering plasma glucagon using **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist, useful for treating hyperglucagonemia and diabetes.

DERWENT CLASS: A25 A96 B04

INVENTOR(S): GEDULIN, B; YOUNG, A

PATENT ASSIGNEE(S): (AMYL-N) AMYLIN PHARM INC

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO 2000041548 A2 20000720 (200043)* EN 96

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000024136 A 20000801 (200054)

NO 2001003469 A 20010914 (200163)
 EP 1143989 A2 20011017 (200169) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 BR 2000007823 A 20011120 (200202)
 KR 2001086165 A 20010908 (200219)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000041548	A2	WO 2000-US942	20000114
AU 2000024136	A	AU 2000-24136	20000114
NO 2001003469	A	WO 2000-US942	20000114
		NO 2001-3469	20010712
EP 1143989	A2	EP 2000-902415	20000114
		WO 2000-US942	20000114
BR 2000007823	A	BR 2000-7823	20000114
		WO 2000-US942	20000114
KR 2001086165	A	KR 2001-708904	20010713

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000024136	A Based on	WO 200041548
EP 1143989	A2 Based on	WO 200041548
BR 2000007823	A Based on	WO 200041548

PRIORITY APPLN. INFO: US 2000-175365P 20000110; US 1999-116380P
 19990114; US 1999-132017P 19990430

AN 2000-490999 [43] WPIDS
 CR 2000-514584 [46]; 2001-514422 [47]
 AB WO 200041548 A UPAB: 20011031

NOVELTY - A new method for lowering plasma glucagon comprises administering a compound (C1) selected from **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist.

ACTIVITY - Antidiabetic; dermatological.

MECHANISM OF ACTION - The compounds lower plasma glucagon level.

The safety, tolerability, and efficacy of synthetic **exendin**

-4 was evaluated in 8 male non-insulin using patients with type 2 diabetes who had discontinued other antidiabetic therapy for a minimum of 7 days. Each patient received subcutaneous (SC) injections of placebo (PBO) and 0.1, 0.2, and 0.3 micro g/kg **exendin**-4 48 hours apart in a single-blind, dose-rising, placebo controlled crossover design. Five patients also received a 0.4 micro g/kg dose. Plasma glucose, insulin and glucagon concentrations were assessed during fasting and in response to a 7 Kcal/kg Sustacal (RTM) challenge administered at the time of **exendin**-4/PBO injection. Gastric emptying was evaluated by measuring serum acetaminophen concentrations following a 20 mg/kg oral dose of liquid acetaminophen administered with the Sustacal (RTM).

No safety issues were identified based upon reported adverse events, EKG (undefined) and safety lab monitoring. Doses of 0.3 and 0.4 micro g/kg elicited a dose-dependent increase in nausea. Vomiting occurred at the highest dose.

Plasma glucose concentrations were reduced in all doses of **exendin**-4 compared to PBO although insulin concentrations were not significantly different. The 8 hour mean plus or minus SE changes in plasma glucose AUC (undefined) from baseline were +391 plus or minus 187, -263 plus or minus 108, -247 plus or minus 64, -336 plus or minus 139, and -328 plus or minus 70 (mg)(hr)/dL for the PBO, 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively. The 3 hour changes in plasma glucagon were +128.0 plus or minus 19.2, -5.6 plus or minus 10.5, -29.4 plus or minus 18.6, -40.5 plus or minus 24.5, and +6.9 plus or minus 38.6 (pg)(hr)/mL respectively. The gastric emptying rate was slowed in all doses and the

mean total absorbed acetaminophen over 6 hours was reduced by 51%, 50%, 57% and 79% compared to PBO for 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively.

In summary, SC injection of **exendin-4** to patients identified no safety issues, was tolerated at doses at most 0.3 micro g/kg, reduced plasma glucose and glucagon and slowed the rate of gastric emptying.

USE - The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma** (claimed). The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

Dwg. 0/6

=>

90 ANSWER 214 OF 216 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:493318 CAPLUS
 DOCUMENT NUMBER: 133:129880
 TITLE: Methods using an **exendin** or related substance for glucagon suppression
 INVENTOR(S): Young, Andrew; Gedulin, Bronislava
 PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041548	A2	20000720	WO 2000-US942	20000114
WO 2000041548	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143989	A2	20011017	EP 2000-902415	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007823	A	20011120	BR 2000-7823	20000114
NO 2001003469	A	20010914	NO 2001-3469	20010712
PRIORITY APPLN. INFO.: US 1999-116380P P 19990114 US 1999-132017P P 19990430 US 2000-175365P P 20000110 WO 2000-US942 W 20000114				

AB Methods are provided for use of an **exendin**, an **exendin** agonist, or a modified **exendin** or **exendin** agonist having an **exendin** or **exendin** agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.

L90 ANSWER 215 OF 216 WPIDS (C) 2002 THOMSON DERWENT
 ACCESSION NUMBER: 2002-012518 [02] WPIDS
 CROSS REFERENCE: 2000-595483 [50]; 2000-680964 [50]
 DOC. NO. CPI: C2002-003289
 TITLE: Use of glycogen phosphorylase inhibitor in prophylactic treatment of Type II diabetes.
 DERWENT CLASS: B02
 INVENTOR(S): TREADWAY, J L
 PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
 COUNTRY COUNT: 31
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1136071	A2	20010926 (200202)*	EN	78	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2001028130	A	20010927 (200202)			
CA 2341344	A1	20010922 (200203)	EN		
JP 2001302546	A	20011031 (200204)		70	
HU 2001001158	A2	20020228 (200223)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1136071	A2	EP 2001-301979	20010305
AU 2001028130	A	AU 2001-28130	20010320
CA 2341344	A1	CA 2001-2341344	20010320
JP 2001302546	A	JP 2001-78839	20010319
HU 2001001158	A2	HU 2001-1158	20010321
KR 2001092696	A	KR 2001-14306	20010320

PRIORITY APPLN. INFO: US 2000-191381P 20000322

AN 2002-012518 [02] WPIDS

CR 2000-595483 [50]; 2000-680964 [50]

AB EP 1136071 A UPAB: 20020114

NOVELTY - A glycogen phosphorylase inhibitor (G1) is used in the manufacture of a medicament for prophylactically treating an individual with increased risk of developing Type II diabetes mellitus

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a pharmaceutical composition comprising (G1) and a non-glycogen phosphorylase inhibiting anti-diabetic agent (NG1); and
- (2) a pharmaceutical composition comprising (G1) and an anti-obesity agent.

ACTIVITY - Antidiabetic.

MECHANISM OF ACTION - Glycogen phosphorylase inhibitor.

No biological data is given.

USE - For prophylactically treating a person having risk associated with Type 2 diabetes (particularly risk associated with insulin resistance and/or hyperinsulinemia; environmental or genetic Type 2 diabetes predisposing disease states or conditions (e.g. person with a family history of diabetes); race and/or ethnicity (e.g. individuals from African-American, Hispanic, Native American, Asian, or Pacific Islander population); genetic mutations affecting beta -cell function (e.g. defect on chromosome 12, gene HNF-1 alpha (MODY3), chromosome 7, gene glucokinase (MODY2), chromosome 20, gene HNF-4a (MODY1), or mitochondrial DNA); genetic defects in insulin action (e.g. genetic mutation leading to Type A insulin resistance, acanthosis nigricans, leprechaunism, Rabson-Mendenhall syndrome, lipoatrophic diabetes, or a genetic mutation or mutations in the insulin receptor, IRS proteins, glucose transporters, PC-1, glucokinase, UCP-1, beta 3 adrenergic receptor gene); presence of excess adipose tissue or clinically diagnosed obesity (e.g. central obesity); clinical chemistry or diagnostic testing signifying a pre-diabetic state (e.g. impaired glucose tolerance, impaired fasting glucose, or hyperglycemia relative to normoglycemia); physiologic and endocrine changes associated with growth, development, or aging (e.g. menopausal, pubescent, or aged individuals); diet or eating behaviors (e.g. consumption of high fat or high carbohydrate diets, experiencing prolonged fasting or starvation, having anorexia nervosa and bulimia); abnormal cardiovascular or blood lipid parameters (e.g. hypertension, HDL cholesterol level upto 35 mg/dl and/or TG levels of at least 250 mg/dl and metabolic syndrome); reproductive status (e.g. pregnancy, a history of gestational diabetes and macrosomia); muscle wasting (e.g. aging, starvation, exposure to anti-gravity environments and paralysis resulting from spinal cord injury); polycystic ovary syndrome; organ disease or dysfunction (e.g. liver cirrhosis and renal disease); metabolic disturbances; endocrine disorders or endocrinopathies (e.g. hyperandrogenism, thyrotoxicosis, hyperthyroidism, insulinoma, glucagonoma, somatostatinoma, aldosteroma, Cushing's Syndrome, pheochromocytoma, acromegaly and hypercortisolemia); pathophysiologic states (e.g. infection, congenital rubella, cytomegalovirus, toxemia, uremia, sepsis and trauma); immune-mediated disease (e.g. stiff man syndrome or the production of anti-insulin receptor antibodies); drug or chemical exposure (e.g. glucocorticoids, cytokines, alpha -interferon,

thyroid hormone, TNF alpha, thiazides, estrogen-containing products, beta-blockers, nicotinic acid, serotonin receptor-targeted antipsychotics or antidepressants, vacor, diazoxide, dilantin, and HIV protease inhibitors); genetic syndrome associated with diabetes (e.g. Down's Syndrome, Klinefelter's Syndrome, Wolfram's Syndrome, Freidreich's Syndrome, Huntington's chorea, Laurence-Moon-Biedl Syndrome, myotonic dystrophy, porphyria, Prader-Willi Syndrome and Alzheimer's Disease); and detrimental effects caused by the administration of prolonged, elevated doses of insulin and/or the presence of ketoacidosis) (all claimed).

Dwg.0/0

L90 ANSWER 216 OF 216 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2000-490999 [43] WPIDS

CROSS REFERENCE: 2000-514584 [46]; 2001-514422 [47]

DOC. NO. CPI: C2000-147547

TITLE: Lowering plasma glucagon using **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist, useful for treating hyperglucagonemia and diabetes.

DERWENT CLASS: A25 A96 B04

INVENTOR(S): GEDULIN, B; YOUNG, A

PATENT ASSIGNEE(S): (AMYL-N) AMYLIN PHARM INC

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000041548	A2	20000720	(200043)*	EN	96
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW				
W:	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW				
AU 2000024136	A	20000801	(200054)		
NO 2001003469	A	20010914	(200163)		
EP 1143989	A2	20011017	(200169)	EN	
R:	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI				
BR 2000007823	A	20011120	(200202)		
KR 2001086165	A	20010908	(200219)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000041548	A2	WO 2000-US942	20000114
AU 2000024136	A	AU 2000-24136	20000114
NO 2001003469	A	WO 2000-US942	20000114
		NO 2001-3469	20010712
EP 1143989	A2	EP 2000-902415	20000114
		WO 2000-US942	20000114
BR 2000007823	A	BR 2000-7823	20000114
		WO 2000-US942	20000114
KR 2001086165	A	KR 2001-708904	20010713

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000024136	A Based on	WO 200041548
EP 1143989	A2 Based on	WO 200041548
BR 2000007823	A Based on	WO 200041548

PRIORITY APPLN. INFO: US 2000-175365P 20000110; US 1999-116380P
19990114; US 1999-132017P 19990430

AN 2000-490999 [43] WPIDS
CR 2000-514584 [46]; 2001-514422 [47]
AB WO 200041548 A UPAB: 20011031

NOVELTY - A new method for lowering plasma glucagon comprises administering a compound (C1) selected from **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist.

ACTIVITY - Antidiabetic; dermatological.

MECHANISM OF ACTION - The compounds lower plasma glucagon level.

The safety, tolerability, and efficacy of synthetic **exendin**

-4 was evaluated in 8 male non-insulin using patients with type 2 diabetes who had discontinued other antidiabetic therapy for a minimum of 7 days. Each patient received subcutaneous (SC) injections of placebo (PBO) and 0.1, 0.2, and 0.3 micro g/kg **exendin**-4 48 hours apart in a single-blind, dose-rising, placebo controlled crossover design. Five patients also received a 0.4 micro g/kg dose. Plasma glucose, insulin and glucagon concentrations were assessed during fasting and in response to a 7 Kcal/kg Sustacal (RTM) challenge administered at the time of **exendin**-4/PBO injection. Gastric emptying was evaluated by measuring serum acetaminophen concentrations following a 20 mg/kg oral dose of liquid acetaminophen administered with the Sustacal (RTM).

No safety issues were identified based upon reported adverse events, EKG (undefined) and safety lab monitoring. Doses of 0.3 and 0.4 micro g/kg elicited a dose-dependent increase in nausea. Vomiting occurred at the highest dose.

Plasma glucose concentrations were reduced in all doses of **exendin**-4 compared to PBO although insulin concentrations were not significantly different. The 8 hour mean plus or minus SE changes in plasma glucose AUC (undefined) from baseline were +391 plus or minus 187, -263 plus or minus 108, -247 plus or minus 64, -336 plus or minus 139, and -328 plus or minus 70 (mg) (hr)/dL for the PBO, 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively. The 3 hour changes in plasma glucagon were +128.0 plus or minus 19.2, -5.6 plus or minus 10.5, -29.4 plus or minus 18.6, -40.5 plus or minus 24.5, and +6.9 plus or minus 38.6 (pg) (hr)/mL respectively. The gastric emptying rate was slowed in all doses and the mean total absorbed acetaminophen over 6 hours was reduced by 51%, 50%, 57% and 79% compared to PBO for 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively.

In summary, SC injection of **exendin**-4 to patients identified no safety issues, was tolerated at doses at most 0.3 micro g/kg, reduced plasma glucose and glucagon and slowed the rate of gastric emptying.

USE - The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma** (claimed). The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

Dwg.0/6

=> s **exendin** and polyethylene
L91 234 FILE DGENE
L92 0 FILE BIOSIS
L93 0 FILE SCISEARCH
L94 3 FILE CAPLUS
L95 0 FILE PROMT
L96 0 FILE MEDLINE
L97 0 FILE EMBASE
L98 0 FILE INVESTTEXT
L99 0 FILE ESBIOBASE
L100 0 FILE DRUGU
L101 0 FILE NLDB
L102 0 FILE PASCAL
L103 1 FILE TOXCENTER
L104 0 FILE BIOTECHNO

L105 0 FILE ADISALERTS
L106 0 FILE PHIN
L107 0 FILE CBNB
L108 3 FILE WPIDS
L109 12 FILE USPATFULL
L110 0 FILE CIN
L111 0 FILE LIFESCI
L112 0 FILE CANCERLIT
L113 0 FILE DRUGNL
L114 0 FILE BIOCOMMERCE
COMMAND INTERRUPTED
L115 0 FILE IFIPAT
L116 0 FILE IMSPROFILES
L117 0 FILE AGRICOLA
L118 0 FILE FEDRIP
L119 0 FILE ADISINSIGHT
L120 0 FILE JICST-EPLUS
L121 0 FILE DRUGUPDATES
L122 0 FILE EMBAL
L123 0 FILE CONFSCI
L124 0 FILE GENBANK
L125 0 FILE BIOBUSINESS
L126 0 FILE FROSTI
L127 0 FILE PHAR
L128 0 FILE ADISNEWS
L129 0 FILE IPA
L130 0 FILE NAPRALERT
L131 0 FILE BIOTECHDS
L132 0 FILE USPAT2
L133 0 FILE BABES

TOTAL FOR ALL FILES

L134 253 EXENDIN AND POLYETHYLENE

If this message appears repeatedly, please notify the Help Desk.

Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> dup rem l134

DUPLICATE IS NOT AVAILABLE IN 'DGENE, INVESTTEXT, BIOCOMMERCE, IMSPROFILES, FEDRIP, ADISINSIGHT, DRUGUPDATES, GENBANK, PHAR, ADISNEWS'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L134

L135 250 DUP REM L134 (3 DUPLICATES REMOVED)

=> d l135 ibib abs

L135 ANSWER 1 OF 250 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:332011 CAPLUS

DOCUMENT NUMBER: 136:355482

TITLE: Compositions comprising a polypeptide and an active agent

INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.

PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-642820 A 20000822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)_n-cephalexin was prep'd. from Glu(OBut)NCA and cephalexin hydrochloride.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

FILE 'HOME' ENTERED AT 11:04:57 ON 03 JUL 2002

=> index bioscience polymers chemistry pharmacology meetings business medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION

0.63 0.63

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...'

ENTERED AT 11:06:35 ON 03 JUL 2002

106 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s exendin and erythema and glucagon

12 FILES SEARCHED...

1 FILE CAPLUS

213 FILE DGENE

39 FILES SEARCHED...

1 FILE WPIDS

1 FILE WPINDEX

73 FILES SEARCHED...

102 FILES SEARCHED...

4 FILES HAVE ONE OR MORE ANSWERS, 106 FILES SEARCHED IN STNINDEX

L1 QUE EXENDIN AND ERYTHEMA AND GLUCAGON

=> file hits

COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION

3.18 3.81

FILE 'DGENE' ENTERED AT 11:10:24 ON 03 JUL 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CAPLUS' ENTERED AT 11:10:24 ON 03 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:10:24 ON 03 JUL 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s 11

L2 213 FILE DGENE

L3 1 FILE CAPLUS

L4 1 FILE WPIDS

TOTAL FOR ALL FILES

L5 215 L1

=> s 15 and glucagonoma

L6 213 FILE DGENE

L7 1 FILE CAPLUS

L8 1 FILE WPIDS

TOTAL FOR ALL FILES

L9 215 L5 AND GLUCAGONOMA

=> dup rem 19
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10 \214 DUP REM L9 (1 DUPLICATE REMOVED)

=> s 110 and exendin
L11 213 S L10
L12 213 FILE DGENE
L13 1 S L10
L14 1 FILE CAPLUS
L15 0 S L10
L16 0 FILE WPIDS

TOTAL FOR ALL FILES
L17 214 L10 AND EXENDIN

=> s 110 and (modified (w) exendin)
L18 213 S L10
L19 213 FILE DGENE
L20 1 S L10
L21 1 FILE CAPLUS
L22 0 S L10
L23 0 FILE WPIDS

TOTAL FOR ALL FILES
L24 214 L10 AND (MODIFIED (W) EXENDIN)

=> s 124 and erythema
L25 213 FILE DGENE
L26 1 FILE CAPLUS
L27 0 FILE WPIDS

TOTAL FOR ALL FILES
L28 214 L24 AND ERYTHEMA

=> s 124 and (necrolytic (w) migratory (w) erythema)
L29 0 FILE DGENE
L30 0 FILE CAPLUS
L31 0 FILE WPIDS

TOTAL FOR ALL FILES
L32 0 L24 AND (NECROLYTIC (W) MIGRATORY (W) ERYTHEMA)

=> s 124 and (MIGRATORY (W) ERYTHEMA)
L33 0 FILE DGENE
L34 0 FILE CAPLUS
L35 0 FILE WPIDS

TOTAL FOR ALL FILES
L36 0 L24 AND (MIGRATORY (W) ERYTHEMA)

=> s 117 and (lowering (w) glucagon)
L37 0 FILE DGENE
L38 1 FILE CAPLUS
L39 0 FILE WPIDS

TOTAL FOR ALL FILES
L40 1 L17 AND (LOWERING (W) GLUCAGON)

=> d 140 ibib abs

L40 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:493318 CAPLUS
 DOCUMENT NUMBER: 133:129880
 TITLE: Methods using an **exendin** or related substance for **glucagon** suppression
 INVENTOR(S): Young, Andrew; Gedulin, Bronislava
 PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041548	A2	20000720	WO 2000-US942	20000114
WO 2000041548	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143989	A2	20011017	EP 2000-902415	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007823	A	20011120	BR 2000-7823	20000114
NO 2001003469	A	20010914	NO 2001-3469	20010712
PRIORITY APPLN. INFO.:			US 1999-116380P	P 19990114
			US 1999-132017P	P 19990430
			US 2000-175365P	P 20000110
			WO 2000-US942	W 20000114

AB Methods are provided for use of an **exendin**, an **exendin** agonist, or a modified **exendin** or **exendin** agonist having an **exendin** or **exendin** agonist linked to one or more polyethylene glycol polymers, for example, for lowering **glucagon** levels and/or suppressing **glucagon** secretion in a subject. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma **glucagon** or suppressing **glucagon** secretion.

=> d 124 1-214 ibib abs

L24 ANSWER 1 OF 214 DGENE (C) 2002 THOMSON DERWENT
 ACCESSION NUMBER: AAY94200 peptide DGENE
 TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist, useful for treating hyperglucagonemia and diabetes -
 INVENTOR: Young A; Gedulin B
 PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
 PATENT INFO: WO 2000041548 A2 20000720 96p
 APPLICATION INFO: WO 2000-US942 20000114
 PRIORITY INFO: US 1999-116380 19990114
 US 1999-132017 19990430
 US 2000-175365 20000110
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-490999 [43]
 AN AAY94200 peptide DGENE
 AB The present sequence represents a modified extendin or extendin agonist.

Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 2 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94199 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94199 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 3 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94198 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94198 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 4 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94197 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94197 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 5 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94196 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94196 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 6 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94195 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94195 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 7 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94194 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94194 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 8 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94193 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94193 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 9 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94192 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94192 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 10 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94191 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94191 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 11 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94190 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94190 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 12 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94189 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94189 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 13 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94188 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94188 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 14 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94187 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94187 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 15 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94186 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94186 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 16 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94185 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94185 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 17 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94184 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94184 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 18 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94183 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94183 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 19 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94182 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94182 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema**

or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 20 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94181 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94181 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 21 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94180 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94180 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating

hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 22 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94179 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94179 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 23 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94178 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94178 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced

glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 24 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94177 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94177 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 25 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94176 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94176 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g.

type 1 and type 2 diabetes.

L24 ANSWER 26 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94175 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94175 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 27 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94174 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94174 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 28 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94173 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94173 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

L24 ANSWER 29 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94172 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94172 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

L24 ANSWER 30 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94171 peptide DGENE
TITLE: Lowering plasma glucagon using exendin,
an exendin agonist, a modified
exendin or a modified exendin
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94171 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 31 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94170 peptide DGENE
TITLE: Lowering plasma glucagon using exendin,
an exendin agonist, a modified
exendin or a modified exendin
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94170 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

ACCESSION NUMBER: AAY94169 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94169 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

L24 ANSWER 33 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94168 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94168 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

L24 ANSWER 34 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94167 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94167 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 35 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94166 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94166 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 36 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94165 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,

an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94165 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 37 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94164 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94164 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 38 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94163 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94163 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 39 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94162 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94162 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 40 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94161 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94161 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 41 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94160 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94160 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 42 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94159 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94159 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 43 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94158 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94158 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 44 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94157 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94157 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 45 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94156 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94156 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 46 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94155 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94155 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 47 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94154 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94154 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 48 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94153 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94153 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 49 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94152 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94152 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 50 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94151 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94151 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 51 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94150 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94150 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 52 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94149 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94149 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 53 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94148 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94148 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 54 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94147 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94147 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist.

Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema**

or **glucagonoma**. The method is also useful for treating

hyperglucagonemia and other conditions that would benefit from reduced

glucagon levels and/or suppression of **glucagon**, e.g.

type 1 and type 2 diabetes.

L24 ANSWER 55 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94146 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94146 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist.

Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema**

or **glucagonoma**. The method is also useful for treating

hyperglucagonemia and other conditions that would benefit from reduced

glucagon levels and/or suppression of **glucagon**, e.g.

type 1 and type 2 diabetes.

L24 ANSWER 56 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94145 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94145 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 57 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94144 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94144 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 58 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94143 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94143 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 59 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94142 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94142 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 60 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94141 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]
AN AAY94141 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 61 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94140 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94140 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 62 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94139 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94139 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 63 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94138 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94138 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 64 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94137 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94137 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 65 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94136 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94136 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 66 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94135 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94135 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.

Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 67 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94134 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94134 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 68 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94133 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94133 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 69 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94132 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94132 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 70 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94131 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94131 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 71 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94130 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94130 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 72 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94129 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94129 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 73 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94128 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94128 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 74 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94127 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94127 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 75 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94126 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94126 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 76 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94125 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94125 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 77 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94124 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94124 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 78 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94123 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94123 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 79 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94122 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94122 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 80 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94121 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94121 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 81 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94120 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94120 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 82 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94119 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94119 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 83 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94118 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94118 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 84 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94117 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94117 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema**

or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 85 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94116 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94116 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 86 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94115 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94115 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating

hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 87 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94114 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94114 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 88 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94113 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94113 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced

glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 89 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94112 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94112 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 90 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94111 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94111 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g.

type 1 and type 2 diabetes.

L24 ANSWER 91 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94110 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114 96p
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94110 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 92 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94109 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114 96p
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94109 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 93 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94108 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94108 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 94 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94107 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94107 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 95 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94106 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94106 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

L24 ANSWER 96 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94105 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94105 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist.
Extendins are found in the salivary glands of the Gila monster and
Mexican Beaded lizard, and have sequence similarity to **glucagon**
-like peptides. They are used in the method of the invention. The
specification describes a method for lowering plasma **glucagon**,
comprising administering an **exendin**, an **exendin**
agonist, a **modified exendin** or a **modified**
exendin agonist. These compounds lower plasma **glucagon**
level. The method is useful for lowering plasma **glucagon** in
subjects, preferably humans, suffering from necrolytic **erythema**
or **glucagonoma**. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of **glucagon**, e.g.
type 1 and type 2 diabetes.

ACCESSION NUMBER: AAY94104 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94104 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 98 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94103 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94103 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 99 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94102 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94102 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 100 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94101 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94101 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 101 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94100 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,

an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94100 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 102 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94099 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94099 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 103 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94098 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94098 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 104 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94097 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94097 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 105 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94096 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94096 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 106 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94095 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94095 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 107 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94094 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94094 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 108 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94093 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94093 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 109 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94092 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94092 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 110 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94091 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94091 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 111 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94090 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94090 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 112 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94089 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94089 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 113 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94088 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94088 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 114 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94087 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94087 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 115 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94086 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94086 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 116 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94085 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94085 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 117 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94084 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94084 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 118 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94083 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94083 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 119 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94082 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94082 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 120 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94081 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94081 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 121 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94080 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94080 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 122 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94079 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94079 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 123 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94078 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94078 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 124 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94077 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94077 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 125 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94076 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]
AN AAY94076 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 126 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94075 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94075 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 127 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94074 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAY94074 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 128 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94073 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94073 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 129 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94072 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94072 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 130 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94071 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94071 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 131 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94070 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94070 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist.

Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 132 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94069 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94069 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 133 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94068 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94068 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 134 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94067 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94067 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 135 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94066 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94066 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 136 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94065 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94065 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 137 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94064 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94064 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 138 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94063 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94063 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 139 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94062 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94062 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 140 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94061 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94061 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 141 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94060 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94060 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 142 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94059 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94059 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 143 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94058 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94058 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 144 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94057 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94057 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 145 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94056 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94056 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 146 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94055 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94055 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 147 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94054 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94054 peptide DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 148 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94053 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94053 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 149 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94052 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94052 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema**

or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 150 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94051 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94051 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 151 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94050 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94050 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating

hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 152 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94049 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94049 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 153 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94048 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94048 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified** **exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced

glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 154 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94047 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94047 peptide DGENE
AB The present sequence represents a modified exendin or exendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2 diabetes.

L24 ANSWER 155 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94046 peptide DGENE
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94046 peptide DGENE
AB The present sequence represents a modified exendin or exendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to glucagon-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma glucagon, comprising administering an exendin, an exendin agonist, a modified exendin or a modified exendin agonist. These compounds lower plasma glucagon level. The method is useful for lowering plasma glucagon in subjects, preferably humans, suffering from necrolytic erythema or glucagonoma. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, e.g.

type 1 and type 2 diabetes.

L24 ANSWER 156 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94045 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94045 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 157 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94044 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94044 peptide DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 158 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94043 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94043 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 159 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94042 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94042 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 160 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94041 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94041 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 161 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94040 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94040 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 162 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94039 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94039 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified**
exendin or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 163 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94038 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94038 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified**
exendin or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 164 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94037 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94037 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 165 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94036 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94036 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified** **exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 166 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94035 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**,

an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94035 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 167 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94034 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94034 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 168 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94033 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94033 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 169 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94032 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94032 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 170 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94031 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin**

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94031 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 171 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94030 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94030 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 172 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94029 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94029 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 173 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94028 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94028 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 174 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94027 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94027 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 175 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94026 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94026 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 176 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94025 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

96p

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94025 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 177 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94024 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94024 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 178 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94023 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94023 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 179 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94022 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94022 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 180 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94021 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94021 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 181 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94020 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94020 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 182 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94019 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94019 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 183 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94018 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94018 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 184 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94017 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94017 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 185 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94016 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAY94016 peptide DGENE

AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 186 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY94015 peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

96p

PATENT INFO: WO 2000041548 A2 20000720

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94015 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 187 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94014 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94014 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 188 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94013 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94013 peptide DGENE
AB AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 189 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94012 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94012 peptide DGENE
AB The present sequence represents an extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 190 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94011 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin**
exendin or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]
AN AAY94011 peptide DGENE
AB The present sequence represents an extendin-4 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 191 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAY94010 peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAY94010 peptide DGENE
AB The present sequence represents an extendin-3 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 192 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAB07488 Peptide DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]

AN AAB07488 Peptide DGENE
AB The present sequence represents an extendin-4 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 193 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07487 Peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07487 Peptide DGENE

AB The present sequence represents an extendin-4 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 194 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07486 Peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07486 Peptide DGENE

AB The present sequence represents an extendin-4 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 195 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07485 Peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07485 Peptide DGENE

AB The present sequence represents an extendin-4 peptide. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 196 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07484 Peptide DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07484 Peptide DGENE

AB The present sequence represents an extendin-4 peptide. Extendins are

found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. It is used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 197 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07417 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07417 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 198 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07416 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07416 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and

Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 199 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07415 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07415 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 200 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07414 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07414 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**

-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 201 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07413 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07413 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 202 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07412 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07412 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The

specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 203 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07411 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07411 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 204 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07410 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N)AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07410 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**,

comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 205 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAB07409 Protein DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAB07409 Protein DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 206 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAB07408 Protein DGENE
TITLE: Lowering plasma **glucagon** using **exendin**,
an **exendin** agonist, a **modified exendin** or a **modified exendin**
agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAB07408 Protein DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon**-like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin**

agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 207 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07407 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07407 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 208 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07406 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720

96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07406 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified**

exendin agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 209 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07405 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07405 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 210 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07404 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07404 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon**

level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 211 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07403 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07403 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 212 OF 214 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAB07402 Protein DGENE

TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -

INVENTOR: Young A; Gedulin B

PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.

PATENT INFO: WO 2000041548 A2 20000720 96p

APPLICATION INFO: WO 2000-US942 20000114

PRIORITY INFO: US 1999-116380 19990114

US 1999-132017 19990430

US 2000-175365 20000110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-490999 [43]

AN AAB07402 Protein DGENE

AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in

subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 213 OF 214 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAB07401 Protein DGENE
TITLE: Lowering plasma **glucagon** using **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist, useful for treating hyperglucagonemia and diabetes -
INVENTOR: Young A; Gedulin B
PATENT ASSIGNEE: (AMYL-N) AMYLIN PHARM INC.
PATENT INFO: WO 2000041548 A2 20000720 96p
APPLICATION INFO: WO 2000-US942 20000114
PRIORITY INFO: US 1999-116380 19990114
US 1999-132017 19990430
US 2000-175365 20000110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-490999 [43]
AN AAB07401 Protein DGENE
AB The present sequence represents a modified extendin or extendin agonist. Extendins are found in the salivary glands of the Gila monster and Mexican Beaded lizard, and have sequence similarity to **glucagon** -like peptides. They are used in the method of the invention. The specification describes a method for lowering plasma **glucagon**, comprising administering an **exendin**, an **exendin** agonist, a **modified exendin** or a **modified exendin** agonist. These compounds lower plasma **glucagon** level. The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic **erythema** or **glucagonoma**. The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

L24 ANSWER 214 OF 214 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:493318 CAPLUS
DOCUMENT NUMBER: 133:129880
TITLE: Methods using an **exendin** or related substance for **glucagon** suppression
INVENTOR(S): Young, Andrew; Gedulin, Bronislava
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041548	A2	20000720	WO 2000-US942	20000114
WO 2000041548	A3	20001130		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			



Creation date: 12-01-2003

Indexing Officer: LCHAU - LINH CHAU

Team: OIPEScanning

Dossier: 09889331

Legal Date: 01-29-2002

No.	Doccode	Number of pages
1	IDS	2
2	1449	4

Total number of pages: 6

Remarks:

Order of re-scan issued on